Can Merck’s Keytruda Start Change In Lung Cancer Market?
Executive Summary
With approval of Merck’s PD-1 inhibitor Keytruda and PD-L1 companion diagnostic in the valuable lung cancer indication, Wall Street’s attention starts turning toward reimbursement and commercialization.